<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="864">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00206700</nctid>
  <trial_identification>
    <studytitle>Open-label Trial of Leukine in Active Crohn's Disease</studytitle>
    <scientifictitle>Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>91274</secondaryid>
    <secondaryid>307340</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sargramostim (Leukine)

Experimental: Arm 1 - 


Treatment: drugs: Sargramostim (Leukine)
Open Label, 8 week cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish a safety profile for long-term, repeated cycles of sargramostim administered to subjects with Crohn's disease.</outcome>
      <timepoint>Not applicable for this outcome</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Crohn's disease activity</outcome>
      <timepoint>After successive 8-week cycles of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of clinical remission and time to disease flare</outcome>
      <timepoint>After successive cycles of sargramostim therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient compliance</outcome>
      <timepoint>After successive cycles of sargramostim therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Able to provide informed consent

          -  Participated in a previous study of sargramostim in Crohn's disease within the past 12
             months

          -  Subjects who participated in protocols excluding concomitant steroid use:

          -  Must have moderately to severely active Crohn's disease at time of screening (CDAI
             score &gt;/= 220 points and less than or equal to 475 points)

          -  Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time
             of screening if treated with corticosteroids between completing their previous
             sargramostim study and entry into this study and be able to taper to less than or
             equal to 7.5 mg daily within one treatment cycle

          -  Subjects who participated in Protocol 307501

          -  Must have active Crohn's disease (CDAI score &gt; 150 points and less than or equal to
             450 points) if completely withdrawn from CS use

          -  Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time
             of screening, be able to taper to less than or equal to 7.5 mg daily within 2
             treatment cycles, and have a CDAI score less than or equal to 450 points if not
             completely withdrawn from CS use

          -  Have a negative serum pregnancy test within 2 weeks prior to receiving initial dose of
             sargramostim in female subjects of child-bearing potential (optional - may be waived
             by the investigator if the subject has had no interruption in contraception method
             since participation in the previous study)

          -  Agree to use of an adequate method of contraception throughout the study period for
             sexually-active males and females of childbearing potential

          -  Able to self-inject sargramostim or have a designee who can do so

          -  Able to comply with protocol requirements

          -  Have a negative stool exam if subject received a course of antibiotics since
             participation in the previous study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or breastfeeding female

          -  Need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal
             obstruction, or intra-abdominal or perianal abscess requiring surgical drainage

          -  Gastrointestinal surgery within the prior 6 months

          -  Symptoms of bowel obstruction or confirmed evidence of a clinically-significant
             stricture within the last 6 months that has not been surgically corrected

          -  Serum creatinine greater than or equal to 2.0 mg/dL

          -  Alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase
             (ALT), or total bilirubin greater or equal to 2X the upper limit of normal; hemoglobin
             (Hb) &lt; 8.0 gm/dL; platelet count greater than or equal to 800,000/mL; ANC less than or
             equal to 1,000/µL or &gt; 20,000/µL (the exclusion of subjects with ANC &gt; 20,000/µL
             applies only to entry into the first treatment cycle)

          -  Use of licensed/registered anti-tumor necrosis factor (TNF) therapy such as infliximab
             within 8 weeks prior to first dose of study drug in this trial

          -  Use of any of the following medications within 4 weeks prior to receiving the first
             dose of study drug: 6-mercaptopurine, azathioprine, cyclophosphamide, methotrexate,
             mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide

          -  Use of any experimental agent in a clinical trial since participating in a
             sargramostim trial

          -  History of allergy to yeast products or sargramostim

          -  Psychiatric illness or substance abuse that would interfere with ability to comply
             with protocol requirements or give informed consent

          -  Clinically important primary disease unrelated to Crohn's disease

          -  Prior exposure to natalizumab (Tysabri)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>378</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital> - Garran</hospital>
    <hospital> - Concord</hospital>
    <hospital> - New Lambton Heights</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Brisbane</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Launceston</hospital>
    <hospital> - Ballarat</hospital>
    <hospital> - Frankston</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Prahran</hospital>
    <hospital> - Fremantle</hospital>
    <hospital> - Penrith</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2200 - Sydney</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4101 - Brisbane</postcode>
    <postcode>5043 - Adelaide</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode>3128 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>2751 - Penrith</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Capital Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Bahia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Parana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Russia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moskva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Waadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnitsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Avon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lothian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>South Glamorgan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne and Wear</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genzyme, a Sanofi Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to establish a safety profile sargramostim administered in 8
      week cycles to adult patients with active Crohn's disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00206700</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Genzyme, a Sanofi Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>